The  Judicial Panel on Multidistrict Litigation has consolidated 13 insulin price-fixing lawsuits and future tag-along cases from states, counties and private entities against three of the largest pharmaceutical companies in the world, who face allegations of over-inflating prices of the insulin they manufacture.

The litigation—consolidated and transferred to the U.S. District Court for the District of New Jersey before Judge Brian Martinotti—could have a far-reaching impact throughout the U.S., where more than 130 million adults are living with diabetes or prediabetes, according to the Centers for Disease Control and Prevention.